Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human trial of Spinal Cord Implantation therapy (regenerative therapy for spinal cord injury)

Next Previous
Trial Profile

A first in human trial of Spinal Cord Implantation therapy (regenerative therapy for spinal cord injury)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous induced pluripotent stem cell based therapy Matricelf (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; First in man

Most Recent Events

  • 21 Mar 2026 New trial record
  • 26 Feb 2026 According to a Matricelf media release, the company received Helsinki Committee approval at Sheba Medical Center to collect blood from patients with complete spinal cord injury, established a clinical advisory board comprised of neurosurgeons and physicians to guide trial design, patient selection criteria, endpoints, and follow-up protocols. The company also signed an agreement with Tel Aviv Sourasky Medical Center (Ichilov) for using dedicated clean rooms in its first clinical study.
  • 26 Feb 2026 According to a Matricelf media release, the company expects to begin identifying eligible patients during 2026, with the goal of completing the first clinical implantation during 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top